Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
  • Pipeline
    • Overview
    • CM24
    • NT219
    • IM1240
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Category: CM-24

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech’s CEO Gil Efron is featured in Pharma’s Almanac sharing his insights in a Q&A executive interview. Read the full Q&A here.
  • Purple Biotech to attend the 17th annual BIO-Europe Spring taking place March 20-22, Basel, Switzerland.
  • Purple Biotech CEO Gil Efron is featured in Drug Development and Delivery Magazine in a Q&A executive interview. Read the full interview.
  • Purple Biotech will attend BIO CEO & Investors conference in NYC and will participate in the panel of “Market Outlook – Convincing Hesitant Investors for IPOs Versus Other Capital Alternatives”.
  • Purple Biotech to participate at the 41st Annual J.P. Morgan week in San Francisco, 9-12 January, 2023
  • CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells
  • Purple Biotech to participate and Present at the Jefferies London Healthcare Conference
  • Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis 
  • Purple Biotech to participate in a leadership call by Chardan Capital Markets LLC. – Click here to replay
  • Interim Safety and Efficacy Results from a Phase 1 Study of NT219 in Adults with Advanced Solid Tumors
CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells

CM24, a Novel Anti-CEACAM1 mAb, Suppresses Neutrophil Extracellular Trap (NET)-Induced Migration and Metastasis of Cancer Cells

By PurpleDev1
in
CM-24
Publications
Nov 16, 2022

Presented at the AACR special conference: Cancer Metastasis, November, 2022

Read more
Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

By PurpleDev1
in
CM-24
Publications
Apr 15, 2022

Presented at the AACR annual meeting April, 2022

Read more
A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer

A Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, followed by a Phase 2a study of CM24 in Combination with Nivolumab in NSCLC, and in Combination with Nivolumab and nab-paclitaxel in Pancreatic Cancer

By yarone
in
CM-24
Publications
Sep 29, 2021

Presented at the ESMO annual meeting 2021

Read more
A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies

A Phase 1 Open-label Multicenter Single Dose Escalation and Multi-dose Study of a mAb Targeting CEACAM1 in Subjects with Selected Advanced or Recurrent Malignancies

By yarone
in
CM-24
Publications
May 01, 2020

Presented at the ASCO annual meeting 2020

Read more
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2021 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset